retifanlimab   Click here for help

GtoPdb Ligand ID: 11583

Synonyms: hPD-1 mAb 7(1.2) [6] | INCMGA0012 | MGA012 | retifanlimab-dlwr | Zynyz®
Approved drug Immunopharmacology Ligand
retifanlimab is an approved drug (FDA (2023), EMA (2024))
Compound class: Antibody
Comment: Retifanlimab (MGA012) is a humanized IgG4 anti-PD-1 monoclonal antibody. It was developed by MacroGenics for anti-cancer potential. Retifanlimab blocks the interaction between PD-1 and its ligands PD-L1/2, and it acts as an immune checkpoint modulator.
Click here for help
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
programmed cell death 1 (CD279) Hs Antibody Binding 8.8 pKd - 6
pKd 8.8 (Kd 1.5x10-9 M) [6]
Description: Binding affinity for immobilised PD-1 determinet bt SPR assay
programmed cell death 1 (CD279) Monkey Antibody Binding 8.3 pKd - 6
pKd 8.3 (Kd 4.6x10-9 M) [6]
Description: Binding affinity for immobilised PD-1 determinet bt SPR assay